Hvivo PLC (HVO) Rating Lowered to Hold at Numis Securities Ltd
Hvivo PLC (LON:HVO) was downgraded by equities research analysts at Numis Securities Ltd to a “hold” rating in a research note issued on Thursday. They currently have a GBX 80 ($1.08) price objective on the stock. Numis Securities Ltd’s price objective points to a potential upside of 3.90% from the stock’s previous close.
Hvivo PLC (HVO) remained flat at GBX 77.00 during midday trading on Thursday. The company had a trading volume of 154 shares. Hvivo PLC has a 12-month low of GBX 105.00 and a 12-month high of GBX 239.75. The stock has a 50 day moving average of GBX 76.50 and a 200-day moving average of GBX 102.60. The stock’s market capitalization is GBX 60.15 million.
Hvivo PLC (LON:HVO) last issued its quarterly earnings data on Thursday, September 21st. The company reported GBX (9.90) (($0.13)) earnings per share for the quarter. Hvivo PLC had a negative net margin of 73.08% and a negative return on equity of 32.75%. The business had revenue of GBX 392 million for the quarter. On average, equities research analysts anticipate that Hvivo PLC will post ($17.00) EPS for the current year.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/23/hvivo-plc-hvo-rating-lowered-to-hold-at-numis-securities-ltd.html.
In other Hvivo PLC news, insider Jaime Ellertson acquired 16,888 shares of the stock in a transaction on Friday, July 7th. The stock was purchased at an average price of GBX 89 ($1.20) per share, for a total transaction of £15,030.32 ($20,264.69).
About Hvivo PLC
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.
Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with MarketBeat.com's FREE daily email newsletter.